Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-MAP2K1/MEK1 Antibody (R1B91)

Catalog #:   RHF95502 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IF, IHC, IP, WB
Accession: Q02750
Overview

Catalog No.

RHF95502

Species reactivity

Human

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000

Target

ERK activator kinase 1, MAP kinase kinase 1, MAP2K1, MAPK/ERK kinase 1, MAPKK 1, MAPKK1, MEK1, MP2K1, PRKMK1, kinase MEK1, MEK1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02750

Applications

IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4 ℃ short term (1-2 weeks). Store at -20 ℃ 12 months. Store at -80 ℃ long term.

Clone ID

R1B91

Data Image
  • Western blot
    All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.
  • Western blot
    All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.
  • Western blot
    All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.
References

Unraveling Botulinum Neurotoxin A Light-Chain-Induced Signaling Pathways: A Phosphoproteomic Analysis in a Controlled Cellular Model., PMID:40507977

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial., PMID:40107157

Ras-MAPK pathway in patients with lupus nephritis., PMID:40102014

E203K mutation in MAP2K1 (MEK1) causes acquired resistance to PD-1 blockade but responds to trametinib: a case report., PMID:39806853

Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions., PMID:39535173

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial., PMID:39313594

Revised Diagnosis From Histiocytic Neoplasm to Optic Chiasm Glioblastoma After Genetic Analysis., PMID:38926909

Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV., PMID:37924647

Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients., PMID:37557922

Case report: Clinicopathological and molecular characteristics of pediatric-type follicular lymphoma., PMID:37539011

Evaluation of the Prognostic Value of Low-Frequency KRAS Mutation Detection in Circulating Tumor DNA of Patients with Metastatic Colorectal Cancer., PMID:37511664

Investigating the effect of MAP2K1 gene (MEK1) in MAPK pathway in the induction of adult T-cell leukemia/lymphoma (ATLL)., PMID:37448673

Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial., PMID:37200022

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer., PMID:37056342

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer., PMID:36921494

Rare molecular subtypes of lung cancer., PMID:36806787

Novel Molecular Therapies and Genetic Landscape in Selected Rare Diseases with Hematologic Manifestations: A Review of the Literature., PMID:36766791

A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study., PMID:36638198

Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders., PMID:36620555

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer., PMID:36419886

Case report: The cardio-facio-cutaneous syndrome due to a novel germline mutation in MAP2K1: A multifaceted disease with immunodeficiency and short stature., PMID:36313893

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer., PMID:36007218

Network Pharmacological Study on the Mechanism of Cynanchum paniculatum (Xuchangqing) in the Treatment of Bungarus multicinctus Bites., PMID:35837378

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer., PMID:35641204

Advances in the Treatment of Hairy Cell Leukemia Variant., PMID:35178674

Current and emerging therapies for advanced biliary tract cancers., PMID:34626563

Circulating tumor DNA sequencing in colorectal cancer patients treated with first-line chemotherapy with anti-EGFR., PMID:34381078

The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice., PMID:34277420

First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis., PMID:33495600

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway., PMID:33436306

Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy., PMID:33322618

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma., PMID:33043759

Immunoglobulin deficiency associated with a MAP2K1-related mutation causing cardio-facio-cutaneous syndrome., PMID:32866538

Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer., PMID:32805066

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance., PMID:32665850

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer., PMID:32047001

Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma., PMID:36046264

Genomic and immune profiling of pre-invasive lung adenocarcinoma., PMID:31784532

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer., PMID:31227518

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents., PMID:31226844

Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae., PMID:30923995

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer., PMID:30777101

Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner., PMID:30394679

Anti-β2 -glycoprotein I antibody with DNA binding activity enters living monocytes via cell surface DNA and induces tissue factor expression., PMID:30368780

Alterations of MEK1/2-ERK1/2, IFNγ and Smad2/3 associated Signalling pathways during cryopreservation of ASCs affect their differentiation towards VSMC-like cells., PMID:30273905

Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand., PMID:30250119

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma., PMID:30115691

Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?, PMID:29851931

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment., PMID:29767411

Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis., PMID:29307797

Datasheet
$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-MAP2K1/MEK1 Antibody (R1B91) [RHF95502]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only